Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Personal Author:
Woodring, Joseph ; Pastore, Roberta ; Brink, Anne ; Ishikawa, Naoko ; Takashima, Yoshihiro ; ... More +
Woodring, Joseph ; Pastore, Roberta ; Brink, Anne ; Ishikawa, Naoko ; Takashima, Yoshihiro ; Tohme, Rania A. Less -
Corporate Authors:
Center for Global Health (U.S.)Global Immunization Division.
Description:
Hepatitis B vaccine (HepB), which has been available since 1982, provides lifelong protection against hepatitis B Virus (HBV) infection and the associated 20%-30% increased lifetime risk for developing cirrhosis or hepatocellular carcinoma among >95% of vaccine recipients (1). Before HepB introduction into national childhood immunization schedules, the estimated hepatitis B surface antigen (HBsAg) prevalence in the World Health Organization (WHO) Western Pacific Region (WPR)* was >8% in 1990 (2). In 2005, the WPR was the first WHO region to establish a hepatitis B control goal, with an initial target of reducing HBsAg prevalence to <2% among children aged 5 years by 2012. In 2013, the WPR set more stringent control targets to achieve by 2017, including reducing HBsAg prevalence to <1% in children aged 5 years and increasing national coverage with both timely HepB birth dose (HepB-BD) (defined as administration within 24 hours of birth) and the third HepB dose (HepB3) to ≥95% (3). All WPR countries/areas endorsed the Regional Action Plan for Viral Hepatitis in the Western Pacific Region 2016-2020 in 2015 (4) and the Regional Framework for the Triple Elimination of Mother-to-Child Transmission of human immunodeficiency Virus (HIV), Hepatitis B and Syphilis in Asia and the Pacific 2018-2030 (triple elimination framework) in 2017 (5). These regional targets and strategies are aligned with program targets established by the WHO Global Health Sector Strategy on Viral Hepatitis 2016-2021 that aim to reduce HBsAg prevalence among children aged 5 years to ≤1% by 2020 and to ≤0.1% by 2030 (6). This report describes progress made to achieve hepatitis B control in the WPR and the steps taken to eliminate mother-to-child Transmission (MTCT) of HBV during 2005-2017. During this period, regional timely HepB-BD and HepB3 coverage increased from 63% to 85% and from 76% to 93%, respectively. As of December 2017, 15 (42%) countries/areas achieved ≥95% timely HepB-BD coverage; 18 (50%) reached ≥95% HepB3 coverage; and 19 (53%) countries/areas as well as the region as a whole were verified to have achieved the regional and global target of <1% HBsAg prevalence among children aged 5 years. Continued implementation of proven vaccination strategies will be needed to make further progress toward WPR hepatitis B control targets. In addition to high HepB-BD and HepB3 coverage, enhanced implementation of complementary hepatitis B Prevention services through the triple elimination framework, including routine HBsAg tTesting of pregnant women, timely administration of hepatitis B immunoglobulin to exposed newborns, and antiviral treatment of mothers with high viral loads, will be needed to achieve the global hepatitis B elimination target by 2030.
Subjects:
[+]
Child, Preschool Disease Eradication Female Full Report Hepatitis B Hepatitis B Surface Antigens Hepatitis B Vaccines Humans Immunization Schedule Infant Infant, Newborn Infectious Disease Transmission, Vertical Pregnancy Seroepidemiologic Studies Surveys And Questionnaires Vaccination Coverage
Source:
MMWR Morb Mortal Wkly Rep. 68(8):195-200
Pubmed ID:
30817746
Pubmed Central ID:
PMC6394384
Document Type:
Journal Article
Place as Subject:
Pacific Islands
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:10dbb2ffc8c26a372b90ce253df8f0fcfff2747cbe82f04d47ea2c18ace27957
Download URL:
https://stacks.cdc.gov/view/cdc/76401/cdc_76401_DS1.pdf
File Type:

Supporting Files

• mm6808a2.nxml

  xml

More +